☰

Joo S. Lee, Ph.D. - Publications

Affiliations: 
2012 Physics and Astronomy Northwestern University, Evanston, IL 
Area:
Theory of complex systems, nonlinear phenomena, statistical physics.
Tree Info Similar researchers PubMed Report error

30 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Lee JS, Nair NU, Dinstag G, Chapman L, Chung Y, Wang K, Sinha S, Cha H, Kim D, Schperberg AV, Srinivasan A, Lazar V, Rubin E, Hwang S, Berger R, et al. Synthetic lethality-mediated precision oncology via the tumor transcriptome. Cell. PMID 33857424 DOI: 10.1016/j.cell.2021.03.030  0.304
2020 Lampert EJ, Cimino-Mathews A, Lee JS, Nair J, Lee MJ, Yuno A, An D, Trepel JB, Ruppin E, Lee JM. Clinical outcomes of prexasertib monotherapy in recurrent wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses. Journal For Immunotherapy of Cancer. 8. PMID 32709712 DOI: 10.1136/Jitc-2019-000516  0.361
2020 Erez A, Ruppin E, Keshet R, Lee JS. Abstract IA21: Blocking purine synthesis in cancer promotes response to immunotherapy Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-Ia21  0.387
2020 Schischlik F, Lee JS, Shah N, Kaplan RN, Thiele CJ, Widemann B, Ruppin E. Abstract A46: Charting the synthetic lethality landscape in pediatric cancer to advance whole-exome precision-based treatments Cancer Research. 80. DOI: 10.1158/1538-7445.Pedca19-A46  0.422
2020 Nair NU, Cheng K, Lee JS, Ruppin E. Abstract 36: Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity Epidemiology. DOI: 10.1158/1538-7445.Am2020-36  0.336
2020 Pathria G, Lee JS, Hasnis E, Tandoc K, Scott DA, Verma S, Feng Y, Larue L, Sahu AD, Topisirovic I, Lopez C, Sears R, Ruppin E, Ronai Z. 1155 Co-Targeting Mapk Signaling And Asparagine Metabolism By Mek Inhibitor + L-Asparaginase Combination In Pancreatic Cancer Gastroenterology. 158. DOI: 10.1016/S0016-5085(20)31266-X  0.308
2019 Wolf Y, Bartok O, Patkar S, Eli GB, Cohen S, Litchfield K, Levy R, Jiménez-Sánchez A, Trabish S, Lee JS, Karathia H, Barnea E, Day CP, Cinnamon E, Stein I, et al. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. Cell. PMID 31522890 DOI: 10.1016/J.Cell.2019.08.032  0.353
2019 Lee JS, Ruppin E. Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1. Jama Oncology. PMID 31436822 DOI: 10.1001/Jamaoncol.2019.2311  0.324
2019 Nair NU, Das A, Rogkoti VM, Fokkelman M, Marcotte R, de Jong CG, Koedoot E, Lee JS, Meilijson I, Hannenhalli S, Neel BG, de Water BV, Le Dévédec SE, Ruppin E. Migration rather than proliferation transcriptomic signatures are strongly associated with breast cancer patient survival. Scientific Reports. 9: 10989. PMID 31358840 DOI: 10.1038/S41598-019-47440-W  0.381
2019 Magen A, Das Sahu A, Lee JS, Sharmin M, Lugo A, Gutkind JS, Schäffer AA, Ruppin E, Hannenhalli S. Beyond Synthetic Lethality: Charting the Landscape of Pairwise Gene Expression States Associated with Survival in Cancer. Cell Reports. 28: 938-948.e6. PMID 31340155 DOI: 10.1016/J.Celrep.2019.06.067  0.386
2019 Feng X, Arang N, Rigiracciolo DC, Lee JS, Yeerna H, Wang Z, Lubrano S, Kishore A, Pachter JA, König GM, Maggiolini M, Kostenis E, Schlaepfer DD, Tamayo P, Chen Q, et al. A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK. Cancer Cell. PMID 30773340 DOI: 10.1016/J.Ccell.2019.01.009  0.323
2019 Lee JS, Ruppin E. Abstract LB-017: Combining tumor mutational burden, CD8+ T-cell abundance and PD1 mRNA expression accurately predicts response to anti-PD1/PDL1 therapy across cancers Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Lb-017  0.307
2019 Das A, Lee JS, Zhang G, Wang Z, Amzallag A, Boland G, Hannenhalli S, Herlyn M, Benes C, Gutkind JS, Flaherty K, Ruppin E. Abstract LB-149: Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Lb-149  0.404
2018 Silberman A, Goldman O, Boukobza Assayag O, Jacob A, Limanovich S, Adler L, Lee JS, Keshet R, Sarver A, Frug J, Stettner N, Galai S, Persi E, Bahar Halpern K, Zaltsman-Amir Y, et al. Acid-induced downregulation of ASS1 contributes to the maintenance of intracellular pH in cancer. Cancer Research. PMID 30573518 DOI: 10.1158/0008-5472.Can-18-1062  0.368
2018 Alon M, Arafeh R, Lee JS, Madan S, Kalaora S, Nagler A, Abgarian T, Greenberg P, Ruppin E, Samuels Y. CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma. Oncotarget. 9: 31264-31277. PMID 30131853 DOI: 10.18632/Oncotarget.25805  0.336
2018 Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nature Medicine. PMID 30127394 DOI: 10.1038/S41591-018-0157-9  0.352
2018 Lee JS, Adler L, Karathia H, Carmel N, Rabinovich S, Auslander N, Keshet R, Stettner N, Silberman A, Agemy L, Helbling D, Eilam R, Sun Q, Brandis A, Malitsky S, et al. Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures. Cell. PMID 30100185 DOI: 10.1016/J.Cell.2018.07.019  0.342
2018 Lee JS, Das A, Jerby-Arnon L, Arafeh R, Auslander N, Davidson M, McGarry L, James D, Amzallag A, Park SG, Cheng K, Robinson W, Atias D, Stossel C, Buzhor E, et al. Harnessing synthetic lethality to predict the response to cancer treatment. Nature Communications. 9: 2546. PMID 29959327 DOI: 10.1038/S41467-018-04647-1  0.352
2018 Tiram G, Ferber S, Ofek P, Eldar-Boock A, Ben-Shushan D, Yeini E, Krivitsky A, Blatt R, Almog N, Henkin J, Amsalem O, Yavin E, Cohen G, Lazarovici P, Lee JS, et al. Reverting the molecular fingerprint of tumor dormancy as a therapeutic strategy for glioblastoma. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. fj201701568R. PMID 29856660 DOI: 10.1096/Fj.201701568R  0.358
2018 Gibori H, Eliyahu S, Krivitsky A, Ben-Shushan D, Epshtein Y, Tiram G, Blau R, Ofek P, Lee JS, Ruppin E, Landsman L, Barshack I, Golan T, Merquiol E, Blum G, et al. Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer. Nature Communications. 9: 16. PMID 29295989 DOI: 10.1038/S41467-017-02283-9  0.301
2018 Lee JS, Carmel N, Karathia H, Auslander N, Rabinovich S, Keshet R, Stettner N, Silberman A, Agemy L, Helbling D, Eilam R, Sun Q, Brandis A, Weiss H, Dimmock D, et al. Abstract A69: Mutagenicity of urea cycle dysregulation and its implications for cancer immunotherapy Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A69  0.432
2018 Lee JS, Das A, Jerby-Arnon L, Arafeh R, Davidson M, Amzallag A, Park SG, Cheng K, Robinson W, Atias D, Stossel C, Buzhor E, Stein G, Waterfall JJ, Meltzer PS, et al. Abstract A188: Harnessing synthetic lethality to predict the response to cancer treatments Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A188  0.413
2018 Nair NU, Das A, Lee JS, Hannenhalli S, Dévédec SL, Water Bvd, Ruppin E. Abstract A023: Cell migration is a stronger predictor of patient survival in breast cancer than cell proliferation Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A023  0.404
2017 Lee JS, Das A, Jerby-Arnon L, Atias D, Amzallag A, Benes CH, Golan T, Ruppin E. Abstract PR09: Harnessing synthetic lethality to predict clinical outcomes of cancer treatment Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-Pr09  0.419
2017 Lee JS, Das A, Jerby-Arnon L, Park SG, Davidson M, Atias D, Amzallag A, Stossel C, Buzhor E, Robinson W, Cheng K, Waterfall JJ, Meltzer PS, Hannenhalli S, Benes CH, et al. Abstract 543: Harnessing synthetic lethality to predict clinical outcomes of cancer treatment Cancer Research. 77: 543-543. DOI: 10.1158/1538-7445.Am2017-543  0.31
2017 Erez A, Silberman A, Jacob A, Limanovich S, Boukobza O, Persi E, Keshet R, Sarver A, Lee JS, Brandis A, Halpern KB, Eilam R, Pode B, Anikster Y, Ulitsky I, et al. Abstract 4987: ASS1 downregulation facilitates cancer cell survival in acidic environment Cancer Research. 77: 4987-4987. DOI: 10.1158/1538-7445.Am2017-4987  0.316
2017 Sahu AD, Lee JS, Ruppin E, Gutkind S, Wang Z. Abstract 3155: Harnessing synthetic rescues to evaluate and mitigate resistance to cancer therapy Cancer Research. 77: 3155-3155. DOI: 10.1158/1538-7445.Am2017-3155  0.304
2016 Cunningham CE, Li S, Vizeacoumar FS, Bhanumathy KK, Lee JS, Parameswaran S, Furber L, Abuhussein O, Paul JM, McDonald M, Templeton SD, Shukla H, El Zawily AM, Boyd F, Alli N, et al. Therapeutic relevance of the protein phosphatase 2A in cancer. Oncotarget. PMID 27557495 DOI: 10.18632/Oncotarget.11399  0.401
2015 Sahu AD, Lee JS, Hannenhalli S, Ruppin E. Abstract B56: Tracing synthetic rescue reprogramming to counteract cancer resistance Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B56  0.408
2011 Cornelius SP, Lee JS, Motter AE. Dispensability of Escherichia coli's latent pathways. Proceedings of the National Academy of Sciences of the United States of America. 108: 3124-9. PMID 21300895 DOI: 10.1073/Pnas.1009772108  0.525
Show low-probability matches.